Developmental Research Program

发展研究计划

基本信息

批准号：
7962164
负责人：
DONALD J. BUCHSBAUM
金额：
$ 8.57万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-03-01 至 2015-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7962164
关键词：
Acute leukemia Attenuated Benchmarking Biological Assay Biometry Brain Breast Budgets Cancer Center Cancer Model Child Clinical Trials Collaborations Collection Colon Carcinoma Commit Correlative Study Data Development Elements Environment Evaluation Extramural Activities Fine needle aspiration biopsy Funding Funding Mechanisms Hepatoblastoma Housing Immune system Immunocompetent Immunotoxins Incidence Informatics Institution Journals Letters Malignant neoplasm of pancreas Minority Mission Modeling Molecular Molecular Genetics Morbidity - disease rate Mus Operative Surgical Procedures Ovarian Pancreas Peer Review Pharmacogenomics Pilot Projects Preventive Medicine Process Progress Reports Publications RNA Records Recruitment Activity Reproducibility Reproduction spores Research Research Personnel Research Project Grants Sampling Scientist Techniques Tissues Training Transgenic Organisms Translational Research Universities University of Alabama at Birmingham Cancer Center Work anticancer research base career development fighting flexibility innovation interest medical schools meetings minority health mortality mouse model novel professor programs success

项目摘要

The mission of the Developmental Research Program (DRP) of the Pancreatic Cancer SPORE is to identify and fund developmental research projects which explore innovative ideas with significant potential to reduce the incidence, morbidity, and mortality of pancreatic cancer. Further, we propose to involve both Morehouse School of Medicine (MSM) and Tuskegee University (TU) in both this program and the Career Development Program of the overall SPORE. Both the Pancreatic SPORE and the UAB Comprehensive Cancer Center (CCC) have successful track records for obtaining and administering developmental research funds. Also, the Division of Preventive Medicine, which houses both the CCC Biostatistics and Informatics Unit and the Minority Health and Research Center, has several years of productive collaboration with both MSM and TU relevant to these programs. The DRP is a most valuable and productive component ofthe UAB Pancreas, Breast, Brain, and prior Ovarian SPORE programs. The development of innovative research ideas in pancreatic cancer is critically dependent on the availability of flexible funding. This Pancreatic Cancer SPORE intends to fund 6 developmental pilot projects annually (two at UAB and four at UMN, including those selected from MSM and TU). The projects will be funded at $50,000/year (6 projects will require $300,000/year). The funds are derived from the proposed SPORE budgets ($50,000 UAB budget and $50,000 UMN budget), UAB institutional funds ($50,000) and UMN institutional funds ($150,000) as described in the institutional letters of commitment. Funding is for 1 year and is renewable for 1 additional year depending on progress. The success of a DRP is determined by its ability to recruit and train junior or new investigators in pancreatic cancer who are committed to translational pancreatic cancer research. The benchmarks for success of the program include participation of awardees in major projects, publication of translational pancreatic cancer research in excellent peer-reviewed journals, and external peer-reviewed funding. A major success of this DRP has been the engagement of UAB and UMN scientists previously not focused specifically on pancreatic cancer. In particular, Dr. Chris Klug is a very good molecular biologist whose major emphasis had been in acute leukemia and leukemic murine models. His project brought his molecular genetic expertise into transgenic pancreatic cancer models, which has progressed to a major Project of this competitive renewal resubmission. Similarly, Dr. Dan Saltzman, Associate Professor of Surgery, has a committed interest in augmentation of the immune system through attenuated Sa/mone//a-lL-2 to fight hepatoblastoma in children. His collaboration with Dr. Chris Klug (Project 1) led to the development of a novel syngeneic immunocompetent pancreatic cancer mouse model, successful IND, and FDA approval ofthe Salmonetla-\L-2 immunotoxin for pancreatic cancer clinical trial with a recently funded (2008) R21. Another DRP success to highlight is Dr. Martin Johnson, whose prior efforts were focused on the pharmacogenomics of FU in colon cancer. Dr. Johnson developed a critical assay via MA-RT-PCR to evaluate nanogram quantities of RNA from pancreatic FNA samples. Dr. Johnson's work has produced two publications documenting the reproducibility and accuracy of the technique and sample acquisition. This has proven to be a critical element of the Tissue Core and has provided further basis for correlative studies proposed in Project 3. The success of this program is also evidenced in that we have 2 pilot studies ongoing at minority institutions

胰腺癌 SPORE 发展研究计划 (DRP) 的使命是确定并资助开发研究项目，探索具有巨大潜力的创新想法，以减少胰腺癌的发病率、发病率和死亡率。此外，我们建议莫尔豪斯和莫尔豪斯都参与其中。医学院 (MSM) 和塔斯基吉大学 (TU) 参与该项目和职业发展 SPORE 总体方案。胰腺 SPORE 和 UAB 综合癌症中心（CCC）在获取和管理发展研究资金方面拥有成功的记录。另外，预防医学部，包括 CCC 生物统计和信息学单位和少数群体健康与研究中心，与 MSM 和 TU 进行了多年富有成效的合作，涉及以下领域：这些程序。 DRP 是 UAB 胰腺、乳房、大脑和先前卵巢中最有价值和最有效的组成部分孢子程序。胰腺癌创新研究理念的发展至关重要关于灵活资金的可用性。这个胰腺癌 SPORE 打算资助 6 个开发试点每年的项目（UAB 两个，UMN 四个，包括从 MSM 和 TU 选出的项目）。这些项目将每年资助 50,000 美元（6 个项目每年需要 300,000 美元）。该资金来自拟议的 SPORE 预算（50,000 美元 UAB 预算和 50,000 美元 UMN 预算）、UAB 机构基金（50,000 美元）和 UMN 机构承诺书中所述的机构资金（150,000 美元）。资助期限为 1 年，并且根据进展情况，可再延长一年。 DRP 的成功取决于其招募和培训胰腺领域初级或新研究人员的能力致力于转化胰腺癌研究的癌症患者。成功的基准计划包括获奖者参与重大项目、出版《转化性胰腺癌》在优秀的同行评审期刊上进行的研究以及外部同行评审的资助。此次活动取得了重大成功 DRP 是 UAB 和 UMN 科学家的参与，此前并未专门关注胰腺癌症。特别是，Chris Klug 博士是一位非常优秀的分子生物学家，他的主要重点是急性白血病和白血病小鼠模型。他的项目将他的分子遗传学专业知识带入转基因胰腺癌模型已成为本次竞争性更新的重大项目重新提交。同样，外科副教授 Dan Saltzman 博士对通过减毒 Sa/mone//a-lL-2 增强免疫系统，对抗儿童肝母细胞瘤。他与 Chris Klug 博士（项目 1）的合作导致了一种新型同基因药物的开发 Salmonetla-\L-2 免疫活性胰腺癌小鼠模型、成功 IND 和 FDA 批准使用最近资助的 (2008) R21 进行胰腺癌免疫毒素临床试验。 DRP 的又一次成功亮点是 Martin Johnson 博士，他之前的工作重点是结肠中 FU 的药物基因组学癌症。 Johnson 博士通过 MA-RT-PCR 开发了一种关键测定法，用于评估来自胰腺 FNA 样本。约翰逊博士的工作已发表两篇出版物，记录了可重复性以及技术和样品采集的准确性。这已被证明是组织的关键要素为项目3提出的相关研究提供了进一步的基础。本项目的成功我们在少数族裔机构正在进行两项试点研究，这也证明了这一点